Pharmaceutical composition for preventing esophageal stenosis

An esophageal stenosis and drug technology, applied in the directions of drug combination, pharmaceutical formula, active ingredient of phosphorus compounds, etc., can solve the problems of insufficient survival rate, inability to take out, low quality of life, etc.

Active Publication Date: 2017-07-07
GUIZHOU YIBAI PHARMA CO LTD +1
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, more than 90% of esophageal cancer patients have progressed to the middle and late stage when diagnosed, the prognosis is poor, and the quality of life is low, and the overall five-year survival rate is less than 20%.
[0006] The main treatment methods for esophageal stenosis include endoscopic balloon or bougie dilation, endoscopic esophageal stent implantation, endoscopic radial incision, etc. However, these treatment methods require repeated treatment, have a certain recurrence rate, Perforation, bleeding, granulation tissue growing into the stent, esophageal ulcer formation, and some stent support force decline and displacement or even cannot be taken out, etc., thus increasing the postoperative pain and medical expenses of patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] 1. Drug combination

[0030] The pharmaceutical combination of the present embodiment is a gel (unit preparation), and the pharmaceutical ingredients are hydrocortisone sodium succinate and aluminum phosphate, and each unit gel contains 50 mg of hydrocortisone sodium succinate and 11 g of aluminum phosphate; The above-mentioned pharmaceutical ingredients can be made into a gel by conventional methods in the art.

[0031] 2. Prevention of esophageal stricture

[0032] Experiments were carried out on multiple patients with large esophagectomy. Among the patients with large esophagectomy, 20% were circumcision patients, 30% were more than 3 / 4 circumcision patients, and 50% were 2 / 3-3 / 4 patients. Patients with circumcision.

[0033] Test method: The above-mentioned drug combination was administered orally to several patients with large esophagectomy; the administration method was: four times a day in the first to second weeks, and the next administration was performed aft...

Embodiment 2

[0036] 1. Drug combination

[0037] The drug combination of the present embodiment is the combination of hydrocortisone sodium succinate powder and aluminum phosphate gel; wherein, hydrocortisone sodium succinate powder contains 50mg of hydrocortisone sodium succinate, aluminum phosphate gel Contains 11g of aluminum phosphate.

[0038] 2. Prevention of esophageal stricture

[0039] Experiments were carried out on multiple patients with large esophagectomy. Among the patients with large esophagectomy, 20% were circumcision patients, 30% were more than 3 / 4 circumcision patients, and 50% were 2 / 3-3 / 4 patients. Patients with circumcision.

[0040] Test method: The above-mentioned drug combination was administered orally to several patients with large esophagectomy; the administration method was: four times a day in the first to second weeks, and the next administration was performed after an interval of 6 hours; Three times a day for one week, the next dose after an interval of 8...

Embodiment 3

[0043] 1. Drug combination

[0044] The pharmaceutical combination of the present embodiment is a suspension, and the pharmaceutical ingredients are hydrocortisone sodium succinate and sucralfate, and each unit suspension contains 50 mg of hydrocortisone sodium succinate and 1 g of sucralfate; The above-mentioned pharmaceutical ingredients are prepared into a suspension in a conventional manner in the art.

[0045] 2. Prevention of esophageal stricture

[0046] Experiments were carried out on multiple patients with large esophagectomy. Among the patients with large esophagectomy, 20% were circumcision patients, 30% were more than 3 / 4 circumcision patients, and 50% were 2 / 3-3 / 4 patients. Patients with circumcision.

[0047] Test method: The above-mentioned drug combination was administered orally to several patients with large esophagectomy; the administration method was: four times a day in the first to second weeks, and the next administration was performed after an interva...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a pharmaceutical composition for preventing esophageal stenosis. The pharmaceutical composition is prepared from glucocorticoid and a mucosal protective component, wherein the glucocorticoid comprises at least one of hydrocortisone sodium succinate, triamcinolone acetonide, dexamethasone and prednisone; the mucosal protective component comprises at least one of aluminum phosphate and sucralfate. The pharmaceutical composition provided by the invention has a good effect of preventing the esophageal stenosis.

Description

technical field [0001] The invention relates to a drug combination, in particular to a drug combination for preventing esophageal stenosis. Background technique [0002] Esophageal cancer is a malignant tumor originating from the epithelium of the esophageal mucosa. It is one of the most common clinical malignant tumors. The incidence of esophageal cancer ranks eighth among malignant tumors worldwide, and its mortality rate ranks sixth. my country is one of the countries with a high incidence of esophageal cancer, with more than 220,000 new cases of esophageal cancer and about 200,000 deaths each year. At present, more than 90% of patients with esophageal cancer have progressed to the middle and late stages when they are diagnosed, with poor prognosis and low quality of life, and the overall five-year survival rate is less than 20%. Therefore, in order to reduce the incidence and mortality of esophageal cancer, it is necessary to effectively identify early cancer and precan...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K33/42A61K31/7024A61P1/00A61K31/573A61K31/58
CPCA61K31/573A61K31/58A61K31/7024A61K33/42A61K45/06A61K2300/00
Inventor 黄永辉闫秀娥周丽雅
Owner GUIZHOU YIBAI PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap